Orally effective methylphenidate extended release powder and aqueous suspension product

  • US 8,956,649 B2
  • Filed: 06/09/2014
  • Issued: 02/17/2015
  • Est. Priority Date: 02/15/2011
  • Status: Active Grant
First Claim
Patent Images

1. A methylphenidate aqueous extended release oral suspension, wherein said suspension has a single mean average plasma concentration peak and a therapeutically effective plasma profile for about 12 hours for d-methylphenidate, andhas a pharmacokinetic profile in which the single mean plasma concentration peak for d-methylphenidate has an area under the curve (AUC)0-∞

  • of about 114 ng-hr/mL to about 180 ng-hr/mL, Cmax of about 11 ng/mL to about 17 ng/mL, Tmax of about 4 hours to about 5.25 hours and T1/2 of about 5 hours to about 7 hours following a single oral administration of an aqueous suspension at a dose equivalent to 60 mg racemic methylphenidate HCl in adults.

View all claims

    Thank you for your feedback